- Home
- NUVL vs ENLC Comparison
NUVL vs ENLC Comparison
Compare NUVL & ENLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ENLC
- Stock Information
- Founded
- NUVL 2017
- ENLC 2013
- Country
- NUVL United States
- ENLC United States
- Employees
- NUVL N/A
- ENLC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ENLC Natural Gas Distribution
- Sector
- NUVL Health Care
- ENLC Utilities
- Exchange
- NUVL Nasdaq
- ENLC Nasdaq
- Market Cap
- NUVL 6.7B
- ENLC 6.7B
- IPO Year
- NUVL 2021
- ENLC N/A
- Fundamental
- Price
- NUVL $87.30
- ENLC $14.25
- Analyst Decision
- NUVL Strong Buy
- ENLC Hold
- Analyst Count
- NUVL 10
- ENLC 11
- Target Price
- NUVL $112.60
- ENLC $15.40
- AVG Volume (30 Days)
- NUVL 350.8K
- ENLC 3.6M
- Earning Date
- NUVL 11-12-2024
- ENLC 11-06-2024
- Dividend Yield
- NUVL N/A
- ENLC 3.73%
- EPS Growth
- NUVL N/A
- ENLC N/A
- EPS
- NUVL N/A
- ENLC 0.22
- Revenue
- NUVL N/A
- ENLC $6,652,200,000.00
- Revenue This Year
- NUVL N/A
- ENLC $1.51
- Revenue Next Year
- NUVL N/A
- ENLC $14.54
- P/E Ratio
- NUVL N/A
- ENLC $64.70
- Revenue Growth
- NUVL N/A
- ENLC N/A
- 52 Week Low
- NUVL $61.80
- ENLC $11.53
- 52 Week High
- NUVL $113.51
- ENLC $16.40
- Technical
- Relative Strength Index (RSI)
- NUVL 36.14
- ENLC 30.69
- Support Level
- NUVL $84.64
- ENLC $14.13
- Resistance Level
- NUVL $89.31
- ENLC $15.55
- Average True Range (ATR)
- NUVL 2.82
- ENLC 0.28
- MACD
- NUVL -0.72
- ENLC -0.15
- Stochastic Oscillator
- NUVL 20.93
- ENLC 5.90
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ENLC EnLink Midstream LLC Common Units representing Limited Partner Interests
EnLink Midstream LLC is an integrated midstream company. The company's operating segment includes Permian; North Texas; Oklahoma; Louisiana and Corporate. The company generates maximum revenue from the Louisiana segment. The Louisiana segment includes natural gas pipelines, natural gas processing plants, storage facilities, fractionation facilities, and NGL assets.